A drug that holds significant promise for treating the devastating effects of hemolytic uremic syndrome (HUS) has been approved for limited use, the U.S. Food and Drug Administration announced Friday. Soliris (generically eculizumab), marketed in…
Continue Reading FDA OKs Drug Offering Hope for HUS Treatment